Lyell Immunopharma, Inc. (LYEL)
USD 0.59
(-7.9%)
USD 0.59
(-7.9%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -163.69 Million | -169.55 Million | -126.24 Million | -160.87 Million | 39.47 Million |
| Net Income | -234.63 Million | -183.11 Million | -250.21 Million | -204.47 Million | -129.37 Million |
| Depreciation & Amortization | 20.25 Million | 18.02 Million | 13.62 Million | 4.29 Million | 1.25 Million |
| Deferred income taxes | 4.83 Million | 2.31 Million | 39.5 Million | -5.61 Million | -1.51 Million |
| Stock-based compensation | 47.08 Million | 81.92 Million | 62.2 Million | 33.26 Million | 15.73 Million |
| Change in working capital | 3.42 Million | -82.01 Million | 4.01 Million | -336 Thousand | 110.8 Million |
| Other non-cash items | -4.65 Million | -6.68 Million | 4.62 Million | 11.99 Million | 42.57 Million |
| Investing Cash Flow | 184.04 Million | -11.54 Million | -121.57 Million | -273.51 Million | -422.43 Million |
| Investments in PPE | -2.68 Million | -24.27 Million | -65.5 Million | -51.48 Million | -16.04 Million |
| Acquisitions | -186.73 Million | -12.73 Million | 673.46 Million | - | - |
| Investment purchases | -476.88 Million | -406.31 Million | -673.46 Million | -43.44 Million | -34 Million |
| Sales/Maturities of investments | 663.61 Million | 419.05 Million | 617.39 Million | 686.32 Million | 238.45 Million |
| Other Investing Activities | 186.73 Million | 12.73 Million | -673.46 Million | -864.9 Million | -610.84 Million |
| Financing Cash Flow | 1.74 Million | 10.63 Million | 401.24 Million | 476.79 Million | 351.15 Million |
| Debt repayment | - | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -457 Thousand | -461 Thousand | - | -16.05 Million | -185 Thousand |
| Common Stock Issuance | 2.2 Million | 9.57 Million | 391.8 Million | 492.84 Million | 351.34 Million |
| Other Financing Activities | 2.2 Million | 1.51 Million | 9.44 Million | 476.79 Million | 351.15 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | 1.46 Million | 667 Thousand | 91 Thousand | -278 Thousand | 1.7 Million |
| Inventory | - | - | - | - | - |
| Other working capital | 1.95 Million | -82.68 Million | 3.92 Million | -58 Thousand | 109.09 Million |
| Cash at beginning of period | 123.83 Million | 294.29 Million | 140.87 Million | 98.47 Million | 130.27 Million |
| Cash at end of period | 145.93 Million | 123.83 Million | 294.29 Million | 140.87 Million | 98.47 Million |
| Capital Expenditure | -2.68 Million | -24.27 Million | -65.5 Million | -51.48 Million | -16.04 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 22.09 Million | -170.46 Million | 153.42 Million | 42.4 Million | -31.8 Million |
| Free Cash Flow | -166.38 Million | -193.83 Million | -191.75 Million | -212.35 Million | 23.42 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -45.8 Million | -60.66 Million | -52.93 Million | -234.63 Million | -50.85 Million | -63.89 Million |
| Depreciation & Amortization | 4.9 Million | 5.02 Million | 5.05 Million | 20.25 Million | 5.1 Million | 5.06 Million |
| Deferred income taxes | - | - | -18.15 Million | 4.83 Million | -1.64 Million | 1.27 Million |
| Stock-based compensation | 8.28 Million | 9.15 Million | 8.46 Million | 47.08 Million | 10.51 Million | 14.22 Million |
| Change in working capital | -954 Thousand | -3.23 Million | 1.72 Million | 3.42 Million | 2.42 Million | 3.58 Million |
| Other non-cash items | 14.08 Million | 27.02 Million | 15.2 Million | -4.65 Million | -3.23 Million | 582 Thousand |
| Investing Cash Flow | 45 Million | 21.99 Million | -100.69 Million | 184.04 Million | 99.67 Million | 152.91 Million |
| Investments in PPE | -331 Thousand | -30 Thousand | -25 Thousand | -2.68 Million | -195 Thousand | -933 Thousand |
| Acquisitions | - | - | 100.66 Million | -186.73 Million | 78.28 Million | 33.25 Million |
| Investment purchases | -116.46 Million | -108.01 Million | -256.78 Million | -476.88 Million | -78.28 Million | -33.25 Million |
| Sales/Maturities of investments | 161.8 Million | 130.03 Million | 156.12 Million | 663.61 Million | 178.14 Million | 187.1 Million |
| Other Investing Activities | 45.33 Million | 22.02 Million | -100.66 Million | 186.73 Million | -78.28 Million | -33.25 Million |
| Financing Cash Flow | 862 Thousand | 27 Thousand | 759 Thousand | 1.74 Million | -143 Thousand | 1.19 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 810 Thousand | -76 Thousand | -123 Thousand | -457 Thousand | -215 Thousand | -50 Thousand |
| Common Stock Issuance | 862 Thousand | 103 Thousand | 882 Thousand | 2.2 Million | 72 Thousand | 1.24 Million |
| Other Financing Activities | 862 Thousand | -76 Thousand | 882 Thousand | 2.2 Million | 72 Thousand | 1.24 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -517 Thousand | -113 Thousand | 425 Thousand | 1.46 Million | -1.41 Million | 380 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -437 Thousand | -3.12 Million | 1.29 Million | 1.95 Million | 3.83 Million | 3.2 Million |
| Cash at beginning of period | 125.65 Million | 145.64 Million | 286.21 Million | 123.83 Million | 224.65 Million | 109.7 Million |
| Cash at end of period | 133.42 Million | 125.65 Million | 145.64 Million | 145.93 Million | 286.49 Million | 224.65 Million |
| Capital Expenditure | -331 Thousand | -30 Thousand | -25 Thousand | -2.68 Million | -195 Thousand | -933 Thousand |
| Effect of forex changes on cash | - | - | -1000.00 | - | -102.39 Million | - |
| Net cash flow / Change in cash | 7.77 Million | -19.99 Million | -140.56 Million | 22.09 Million | 61.84 Million | 114.94 Million |
| Free Cash Flow | -38.42 Million | -42.04 Million | -40.66 Million | -166.38 Million | -37.88 Million | -40.09 Million |
FORSE
600685
TTLPF
MLB1
ITMZF
2289